Advertisement
Organisation › Details
Promethera Biosciences S.A.
Promethera is a global innovator in severe liver diseases and the leader in liver cell-based medicines whose mission is to help overcome acute and chronic liver diseases. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immunemodulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies to complement and diversify our therapeutic options. We are a team of international experts operating out of R&D and GMP facilities in Mont-Saint-Guibert, Belgium, and Durham, NC, USA. Promethera®, HepaStem®, H2stem®, Cytonet®, Heparesc® are all registered trademarks of the PROMETHERA group. *
Start | 2009-02-12 splitoff | |
End | 2021-06-30 renamed (reorg)? | |
Group | Promethera (Group) | |
Predecessor | Université Catholique de Louvain (UCLouvain) | |
Industry | HepaStem cell therapy product | |
Industry 2 | stem cell technology | |
Person | Tchelingerian, John (Promethera 201509– CEO before Silver Ocean Ventures + Neurotech + Diatos) | |
Street | 11 Rue Granbonpré Watson & Crick Hill | |
City | 1435 Mont-Saint-Guibert | |
Tel | +32-10-394300 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Promethera Biosciences S.A.. (4/10/18). "Press Release: Promethera Biosciences Acquires Baliopharm AG to Strengthen its Therapeutic Strategy in NASH With a Unique Tumor Necrosis Factor Receptor 1 (TNF-R1) Antibody Drug Candidates". Mont-Saint-Guibert & B | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Promethera (Group)
- [1] Promethera Therapeutics S.A.. (6/30/21). "Press Release: Walloon Company Promethera Announces a €20 Million Financing Round". Mont-Saint-Guibert....
- [2] Promethera Biosciences S.A.. (4/10/18). "Press Release: Promethera Biosciences Acquires Baliopharm AG to Strengthen its Therapeutic Strategy in NASH With a Unique Tumor Necrosis Factor Receptor 1 (TNF-R1) Antibody Drug Candidates". Mont-Saint-Guibert & B...
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top